See the published version of this preprint at BMC Infectious Diseases.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Zhancheng Gao
Peking University People's Hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: To investigate the long-term effects of SARS-CoV-1 on patients’ lung and immune systems 15 years post-infection.
Methods: We enrolled 58 health care workers with confirmed SARS in Peking University People’s Hospital in 2003. We evaluated lung damage by mMRC score, pulmonary function tests, and chest CT. Immune function was assessed by their serum levels of globin, complete components, and peripheral T cell subsets. ELISA was used to detect SARS-CoV-specific IgG antibodies in sera.
Results: After 15 years of disease onset, 19 (36.5%), 8 (34.6%), and 19 (36.5%) subjects had impaired DL(CO), RV, and FEF25-75, respectively. 17 (30.4%) subjects had an mMRC score ≥ 2. Fourteen (25.5%) cases had residual CT abnormalities. T regulatory cells were a bit higher in the SARS survivors. IgG antibodies against SARS S-RBD protein and N protein were detected in 11 (18.97%) and 12 (20.69%) subjects, respectively. Subgroup analysis revealed that small airway dysfunction and CT abnormalities were more common in the severe group than in the non-severe group (57.1% vs 22.6%, 54.5% vs 6.1%, respectively, p < 0.05).
Conclusions: SARS-CoV-1 could cause permanent damage to the lung, which requires early pulmonary rehabilitation. The long-lived immune memory response against coronavirus requires further studies to assess the potential benefit.
Trail registration: ClinicalTrials.gov, NCT03443102. Registered prospectively on 22/02/2018.
Keywords
Severe acute respiratory syndrome (SARS), SARS-CoV specific IgG antibody, Regulatory T cell, HRCT, pulmonary function test
Figure 1
Figure 2
Figure 3
Figure 4
No competing interests reported.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Infectious Diseases.
Version 1
Posted 12 May, 2021
No community comments so far
Editorial decision: Major revision
On 30 Sep, 2021
Reviews received
Received 19 Sep, 2021
Reviewers agreed
On 09 Sep, 2021
Reviews received
Received 24 Jun, 2021
Reviewers agreed
On 23 Jun, 2021
Reviewers agreed
On 26 May, 2021
Reviewers invited
Invitations sent on 24 May, 2021
Editor assigned
On 19 May, 2021
Editor invited
On 11 May, 2021
Submission checks complete
On 11 May, 2021
First submitted
On 02 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Infectious Diseases.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Zhancheng Gao
Peking University People's Hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Infectious Diseases.
Version 1
Posted 12 May, 2021
No community comments so far
Editorial decision: Major revision
On 30 Sep, 2021
Reviews received
Received 19 Sep, 2021
Reviewers agreed
On 09 Sep, 2021
Reviews received
Received 24 Jun, 2021
Reviewers agreed
On 23 Jun, 2021
Reviewers agreed
On 26 May, 2021
Reviewers invited
Invitations sent on 24 May, 2021
Editor assigned
On 19 May, 2021
Editor invited
On 11 May, 2021
Submission checks complete
On 11 May, 2021
First submitted
On 02 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Infectious Diseases.
Background: To investigate the long-term effects of SARS-CoV-1 on patients’ lung and immune systems 15 years post-infection.
Methods: We enrolled 58 health care workers with confirmed SARS in Peking University People’s Hospital in 2003. We evaluated lung damage by mMRC score, pulmonary function tests, and chest CT. Immune function was assessed by their serum levels of globin, complete components, and peripheral T cell subsets. ELISA was used to detect SARS-CoV-specific IgG antibodies in sera.
Results: After 15 years of disease onset, 19 (36.5%), 8 (34.6%), and 19 (36.5%) subjects had impaired DL(CO), RV, and FEF25-75, respectively. 17 (30.4%) subjects had an mMRC score ≥ 2. Fourteen (25.5%) cases had residual CT abnormalities. T regulatory cells were a bit higher in the SARS survivors. IgG antibodies against SARS S-RBD protein and N protein were detected in 11 (18.97%) and 12 (20.69%) subjects, respectively. Subgroup analysis revealed that small airway dysfunction and CT abnormalities were more common in the severe group than in the non-severe group (57.1% vs 22.6%, 54.5% vs 6.1%, respectively, p < 0.05).
Conclusions: SARS-CoV-1 could cause permanent damage to the lung, which requires early pulmonary rehabilitation. The long-lived immune memory response against coronavirus requires further studies to assess the potential benefit.
Trail registration: ClinicalTrials.gov, NCT03443102. Registered prospectively on 22/02/2018.
Figure 1
Figure 2
Figure 3
Figure 4
No competing interests reported.
Loading...